These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 24243565)

  • 1. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
    Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
    Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
    Gökmen-Polar Y; Liu Y; Toroni RA; Sanders KL; Mehta R; Badve S; Rommel C; Sledge GW
    Breast Cancer Res Treat; 2012 Dec; 136(3):673-82. PubMed ID: 23085766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
    Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK
    Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.
    Hassan B; Akcakanat A; Sangai T; Evans KW; Adkins F; Eterovic AK; Zhao H; Chen K; Chen H; Do KA; Xie SM; Holder AM; Naing A; Mills GB; Meric-Bernstam F
    Oncotarget; 2014 Sep; 5(18):8544-57. PubMed ID: 25261369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.
    Harada K; Miyake H; Kumano M; Fujisawa M
    Br J Cancer; 2013 Oct; 109(9):2389-95. PubMed ID: 24091619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.
    Guo Y; Kwiatkowski DJ
    Mol Cancer Res; 2013 May; 11(5):467-73. PubMed ID: 23386687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
    Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL
    PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.
    Zheng B; Mao JH; Qian L; Zhu H; Gu DH; Pan XD; Yi F; Ji DM
    Cancer Lett; 2015 Feb; 357(2):468-75. PubMed ID: 25444920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.
    Kannan A; Lin Z; Shao Q; Zhao S; Fang B; Moreno MA; Vural E; Stack BC; Suen JY; Kannan K; Gao L
    Oncotarget; 2016 Feb; 7(6):6576-92. PubMed ID: 26536665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma.
    Bailey ST; Zhou B; Damrauer JS; Krishnan B; Wilson HL; Smith AM; Li M; Yeh JJ; Kim WY
    PLoS One; 2014; 9(9):e104413. PubMed ID: 25180793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.
    Caro-Vegas C; Bailey A; Bigi R; Damania B; Dittmer DP
    mBio; 2019 Feb; 10(1):. PubMed ID: 30782662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
    Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
    Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.
    Zeng Z; Wang RY; Qiu YH; Mak DH; Coombes K; Yoo SY; Zhang Q; Jessen K; Liu Y; Rommel C; Fruman DA; Kantarjian HM; Kornblau SM; Andreeff M; Konopleva M
    Oncotarget; 2016 Aug; 7(34):55083-55097. PubMed ID: 27391151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.
    Cho DC; Cohen MB; Panka DJ; Collins M; Ghebremichael M; Atkins MB; Signoretti S; Mier JW
    Clin Cancer Res; 2010 Jul; 16(14):3628-38. PubMed ID: 20606035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.
    Miyahara H; Yadavilli S; Natsumeda M; Rubens JA; Rodgers L; Kambhampati M; Taylor IC; Kaur H; Asnaghi L; Eberhart CG; Warren KE; Nazarian J; Raabe EH
    Cancer Lett; 2017 Aug; 400():110-116. PubMed ID: 28450157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
    Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
    Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.
    Plimack ER; Tan T; Wong YN; von Mehren MM; Malizzia L; Roethke SK; Litwin S; Li T; Hudes GR; Haas NB
    Oncologist; 2014 Apr; 19(4):354-5. PubMed ID: 24674872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
    Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
    Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.